Deutsche Bank
TVTX icon

Deutsche Bank’s Travere Therapeutics TVTX Stock Holding History

Deutsche Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-450
Closed -$5K – 5918
2014
Q4 		$5K Hold
450
– – ﹤0.01% 5883
2014
Q3 		$4K Buy
+450
New +$5.29K ﹤0.01% 5576

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank's TVTX Position: Q1 2026 in Review

Deutsche Bank increased its Travere Therapeutics (TVTX) stake by 5% in Q1 2026, buying an estimated $1.32M and bringing the position to 925,919 shares worth $27.5M. The position accounts for 0.01% of the portfolio, ranked #767.

Deutsche Bank first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $38.2M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Deutsche Bank held 925,919 shares of Travere Therapeutics worth $27.5M as of Q1 2026.
  • Deutsche Bank bought 44,239 Travere Therapeutics shares in Q1 2026, an estimated $1.32M.
  • Travere Therapeutics made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #767 holding.
  • Deutsche Bank first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Deutsche Bank's Travere Therapeutics position peaked at $38.2M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.